

Outlook Therapeutics, Inc. Logo

## Outlook Therapeutics Announces Closing of \$10.2 Million Financings Priced At-The-Market

February 26, 2020

CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 7,598,426 shares of its common stock, at a combined purchase price of \$1.016 per share and associated unregistered warrant, for aggregate gross proceeds of approximately \$7.72 million. The Company also issued to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 3,799,213 shares of its common stock. The warrants have an exercise price of \$0.9535 per share of common stock, are exercisable on the date of issuance, and will expire four years following the date of issuance.

H.C. Wainwright & Co. acted as the exclusive placement agent.

In addition, the Company has closed the private placement priced at-the-market under Nasdaq rules with an affiliate of BioLexis Pte. Ltd. ("BioLexis"), its controlling stockholder and strategic partner, of 2,460,630 shares of its common stock and warrants to purchase up to 1,230,315 shares of its common stock, at a combined purchase price of \$1.016 per share and associated warrant, for aggregate gross proceeds of approximately \$2.5 million. The warrants have an exercise price of \$0.9535 per share of common stock, are exercisable on the date of issuance, and will expire four years following the date of issuance.

Outlook Therapeutics intends to use the net proceeds from the financings for working capital and general corporate purposes, including in support of its ONS-5010 development program.

The shares of common stock (but not the warrants or the shares of common stock underlying such warrants) offered in the registered direct offering were offered and sold by the Company pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-231922), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on June 26, 2019. The offering of the shares of common stock in the registered direct transaction was made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering has been filed with the SEC and is available on the SEC's website located at <http://www.sec.gov>. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at [placements@hcwco.com](mailto:placements@hcwco.com).

The securities in the private placement and the warrants in the registered direct offering (and the shares of common stock underlying such warrants) were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and/or Regulation D promulgated thereunder, and such securities have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Outlook has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issuable upon the exercise of the warrants issued in the registered direct offering. Additionally, the shares of common stock and the shares of common stock issuable upon the exercise of warrants in the private placement with the investor affiliated with BioLexis have registration rights under an existing Investor Rights Agreement, which was amended concurrent with the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

### About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010, its investigational ophthalmic formulation of bevacizumab, is approved, Outlook Therapeutics expects to commercialize it as the first and only on-label approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, Europe, Japan and other markets.

### Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "project," "believe," "estimate," "predict," "potential," "intend" or "continue," the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include statements about FDA approval of ONS-5010 and expected commercial launch. Although the Company believes that it has a reasonable basis for forward-looking statements contained herein, they are based on current expectations about future events affecting the Company and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, as well as those risks detailed in the Company's filings with the Securities and Exchange Commission. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

### CONTACTS:

**Outlook Therapeutics:**

Lawrence A. Kenyon  
Chief Executive Officer and Chief Financial Officer  
[LawrenceKenyon@outlooktherapeutics.com](mailto:LawrenceKenyon@outlooktherapeutics.com)

**Media Inquiries:**

Emmie Twombly  
Media Relations Specialist  
LaVoie Health Science  
M: 857.389.6042  
[etwombly@lavoiehealthscience.com](mailto:etwombly@lavoiehealthscience.com)

**Investor Inquiries:**

Jeremy Feffer  
Managing Director  
LifeSci Advisors, LLC  
T: 212.915.2568  
[jeremy@lifesciadvisors.com](mailto:jeremy@lifesciadvisors.com)



Source: Outlook Therapeutics, Inc.